Frontier Biotechnologies Inc. Class ASSE: 688221

Voluntary Disclosure Announcement on Approval of Phase II Clinical Trial for New Indication of Immune Reconstitution Insufficient of Aikening

· Issued by Frontier Biotechnologies Inc. Class A via Shanghai Stock Exchange
Voluntary Disclosure Announcement on Approval Notice of Phase II Clinical Trial for New Indication of Incomplete Immune Reconstitution of Aikening

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis